Amgen Inc. Stock News

Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for som

Amgen's revenue growth hasn't been very good of late. The company is working on rejuvenating its lineup.

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Amgen's earnings are reliable, and derived from a bunch of different medicines. It spends a relatively small proportion of its resources on developing new drugs.

Amgen has delivered a 647% total return since 2011 and maintained a solid 10.04% 5-Year Dividend Growth Rate. Amid short-term product decisions and sales variations driving down operational efficiency

Amgen is treating cancers using a new therapeutic modality. It's planning on producing a few more therapies in the same vein.

In the latest trading session, Amgen (AMGN) closed at $310.26, marking a +1.56% move from the previous day.

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUM, Elevance Health Inc. NYSE: ELV, Incyte Corp. NASDAQ: INCY, Insulet Corp.

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

Amgen's stock price has surged, driven by strategic acquisitions, a diverse medical portfolio, and a focus on AI innovation, positioning it for substantial long-term growth. Amgen's strong performance